Ann N Y Acad Sci. 2009 Dec;1182:80-7.

Interferon lambda as a potential new therapeutic for hepatitis C.

Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE.

Source

ZymoGenetics, Inc., Seattle, Washington 98102, USA. millerd@zgi.com

Abstract

Interferon lambdas (IFN-lambda) are Type III interferons with biological activity, including induction of antiviral genes, similar to Type I IFNs, but signal through a distinct receptor complex. The expression pattern for the IFN-lambda receptor is more cell specific than the widely distributed IFN-alpha receptor, suggesting in vivo, IFN-lambda may have fewer side effects than IFN-alpha, such as less hematologic toxicities. A PEGylated form of IFN-lambda (PEG-rIL-29) was well tolerated in animals and did not result in hematologic toxicity. Clinical data from initial studies of PEG-rIL-29 has demonstrated antiviral effects in patients with hepatitis C without producing hematologic toxicity. These preclinical and early clinical data support PEG-rIL-29 as a potential new therapeutic agent for treatment of patients with hepatitis C.

PMID:: 20074277; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Hepatitis C - MedlinePlus Health Information

Supplemental Content

Related citations

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. [Gastroenterology. 2006]
Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. Gastroenterology. 2006 Dec; 131(6):1887-98. Epub 2006 Oct 1.
Review Interferon-lambda: a new addition to an old family. [J Interferon Cytokine Res. 2010]
Review Interferon-lambda: a new addition to an old family.
Donnelly RP, Kotenko SV. J Interferon Cytokine Res. 2010 Aug; 30(8):555-64.
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. [J Gastroenterol Hepatol. 2005]
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
Toniutto P, Fabris C, Fumo E, Apollonio L, Caldato M, Avellini C, Minisini R, Pirisi M. J Gastroenterol Hepatol. 2005 Apr; 20(4):577-82.
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. [J Virol. 2006]
Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo.
Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. J Virol. 2006 May; 80(9):4501-9.
Review Interferon-lambda as a potential therapeutic agent in cancer treatment. [J Interferon Cytokine Res. 2010]
Review Interferon-lambda as a potential therapeutic agent in cancer treatment.
Steen HC, Gamero AM. J Interferon Cytokine Res. 2010 Aug; 30(8):597-602.

See reviews... See all...

Cited by 2 PubMed Central articles

Interferon-λ in HCV Infection and Therapy. [Viruses. 2010]
Interferon-λ in HCV Infection and Therapy.
Pagliaccetti NE, Robek MD. Viruses. 2010 Aug; 2(8):1589-602. Epub 2010 Aug 5.
Review Interferon-lambda: a new addition to an old family. [J Interferon Cytokine Res. 2010]
Review Interferon-lambda: a new addition to an old family.
Donnelly RP, Kotenko SV. J Interferon Cytokine Res. 2010 Aug; 30(8):555-64.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Interferon lambda as a potential new therapeutic for hepatitis C.
Interferon lambda as a potential new therapeutic for hepatitis C.
Ann N Y Acad Sci. 2009 Dec ;1182:80-7.

PubMed
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in pat...
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
Hepatology. 2010 Sep ;52(3):822-32.

PubMed
Physician respect for patients with obesity.
Physician respect for patients with obesity.
J Gen Intern Med. 2009 Nov ;24(11):1236-9. Epub 2009 Sep 18 .

PubMed
Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseu...
Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery?
Cell Cycle. 2008 Jun 1 ;7(11):1575-9. Epub 2008 Mar 31 .

PubMed
Influenza A virus (A/Yamaguchi/22/2009(H1N1)) segment 6 neuraminidase (NA) gene,...
Influenza A virus (A/Yamaguchi/22/2009(H1N1)) segment 6 neuraminidase (NA) gene, complete cds
gi|254548843|gb|GQ397279.1|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: